Description: Antisense Therapeutics Limited, a biopharmaceutical drug discovery and development company, engages in the research and development of antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 that has completed Phase IIa for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of CD49d for the treatment of inflammation associated with duchenne muscular dystrophy. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
Home Page: www.antisense.com.au
14 Wallace Avenue
Toorak,
VIC
3142
Australia
Phone:
61 3 9827 8999
Officers
| Name | Title |
|---|---|
| Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD | CEO, MD & Director |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Joint Company Sec. |
| Dr. George Tachas | Director of Drug Discovery & Patents |
| Ms. Nuket Desem | Director of Clinical and Regulatory affairs |
| Dr. Anthony Filippis | Chief Commercial Officer |
| Ms. Alicia Mellors | Joint Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0474 |
| Price-to-Sales TTM: | 24.4602 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |